National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

Catharine M. Sturgeon; Michael J. Duffy; Ulf-Håkan Stenman; Hans Lilja; Nils Brünner; Daniel W. Chan; Richard Babaian; Robert C. Bast; Barry Dowell; Francisco J. Esteva; Caj Haglund; Nadia Harbeck; Daniel F. Hayes; Mads Nikolaj Holten-Andersen; George G Klee; Rolf Lamerz; Leendert H Looijenga; Rafael Molina; Hans Jørgen Nielsen; Harry Rittenhouse; Axel Semjonow; Ie-Ming Shih; Paul Sibley; György Sölétormos; Carsten Stephan; Lori Sokoll; Barry R. Hoffman; Eleftherios P. Diamandis; Catharine M Sturgeon; Michael J Duffy; Ulf-Håkan Stenman; Hans Lilja; Nils Brünner; Daniel W Chan; Richard Babaian; Robert C Bast; Barry Dowell; Francisco J Esteva; Caj Haglund; Nadia Harbeck; Daniel F Hayes; Mads Holten-Andersen; George G Klee; Rolf Lamerz; Leendert H Looijenga; Rafael Molina; Hans Jørgen Nielsen; Harry Rittenhouse; Axel Semjonow; Ie-Ming Shih; Paul Sibley; György Sölétormos; Carsten Stephan; Lori Sokoll; Barry R Hoffman; Eleftherios P Diamandis; NN NN

doi:10.1373/clinchem.2008.105601

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

Catharine M. Sturgeon, Michael J. Duffy, Ulf-Håkan Stenman, Hans Lilja, Nils Brünner, Daniel W. Chan, Richard Babaian, Robert C. Bast, Barry Dowell, Francisco J. Esteva, Caj Haglund, Nadia Harbeck, Daniel F. Hayes, Mads Nikolaj Holten-Andersen, George G Klee, Rolf Lamerz, Leendert H Looijenga, Rafael Molina, Hans Jørgen Nielsen, Harry RittenhouseAxel Semjonow, Ie-Ming Shih, Paul Sibley, György Sölétormos, Carsten Stephan, Lori Sokoll, Barry R. Hoffman, Eleftherios P. Diamandis, Catharine M Sturgeon, Michael J Duffy, Ulf-Håkan Stenman, Hans Lilja, Nils Brünner, Daniel W Chan, Richard Babaian, Robert C Bast, Barry Dowell, Francisco J Esteva, Caj Haglund, Nadia Harbeck, Daniel F Hayes, Mads Holten-Andersen, George G Klee, Rolf Lamerz, Leendert H Looijenga, Rafael Molina, Hans Jørgen Nielsen, Harry Rittenhouse, Axel Semjonow, Ie-Ming Shih, Paul Sibley, György Sölétormos, Carsten Stephan, Lori Sokoll, Barry R Hoffman, Eleftherios P Diamandis, NN NN

Department of Clinical Medicine

423 Citations (Scopus)

Abstract

BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed. RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node-negative patients. CA15-3/BR27-29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.

Original language	English
Journal	Clinical Chemistry
Volume	54
Issue number	12
Pages (from-to)	e11-79
ISSN	0009-9147
DOIs	https://doi.org/10.1373/clinchem.2008.105601 https://doi.org/10.1373/clinchem.2008.105601
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

Sturgeon, C. M., Duffy, M. J., Stenman, U-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M. N., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., ... NN, NN. (2008). National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical Chemistry, 54(12), e11-79. https://doi.org/10.1373/clinchem.2008.105601, https://doi.org/10.1373/clinchem.2008.105601

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. / Sturgeon, Catharine M.; Duffy, Michael J.; Stenman, Ulf-Håkan et al.

In: Clinical Chemistry, Vol. 54, No. 12, 2008, p. e11-79.

Research output: Contribution to journal › Journal article › Research › peer-review

Sturgeon, CM, Duffy, MJ, Stenman, U-H, Lilja, H, Brünner, N, Chan, DW, Babaian, R, Bast, RC, Dowell, B, Esteva, FJ, Haglund, C, Harbeck, N, Hayes, DF, Holten-Andersen, MN, Klee, GG, Lamerz, R, Looijenga, LH, Molina, R, Nielsen, HJ, Rittenhouse, H, Semjonow, A, Shih, I-M, Sibley, P, Sölétormos, G, Stephan, C, Sokoll, L, Hoffman, BR, Diamandis, EP, Sturgeon, CM, Duffy, MJ, Stenman, U-H, Lilja, H, Brünner, N, Chan, DW, Babaian, R, Bast, RC, Dowell, B, Esteva, FJ, Haglund, C, Harbeck, N, Hayes, DF, Holten-Andersen, M, Klee, GG, Lamerz, R, Looijenga, LH, Molina, R, Nielsen, HJ, Rittenhouse, H, Semjonow, A, Shih, I-M, Sibley, P, Sölétormos, G, Stephan, C, Sokoll, L, Hoffman, BR, Diamandis, EP & NN, NN 2008, 'National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers', Clinical Chemistry, vol. 54, no. 12, pp. e11-79. https://doi.org/10.1373/clinchem.2008.105601, https://doi.org/10.1373/clinchem.2008.105601

@article{53aad870cd0c11dd9473000ea68e967b,

title = "National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers",

abstract = "BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed. RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node-negative patients. CA15-3/BR27-29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.",

author = "Sturgeon, {Catharine M.} and Duffy, {Michael J.} and Ulf-H{\aa}kan Stenman and Hans Lilja and Nils Br{\"u}nner and Chan, {Daniel W.} and Richard Babaian and Bast, {Robert C.} and Barry Dowell and Esteva, {Francisco J.} and Caj Haglund and Nadia Harbeck and Hayes, {Daniel F.} and Holten-Andersen, {Mads Nikolaj} and Klee, {George G} and Rolf Lamerz and Looijenga, {Leendert H} and Rafael Molina and Nielsen, {Hans J{\o}rgen} and Harry Rittenhouse and Axel Semjonow and Ie-Ming Shih and Paul Sibley and Gy{\"o}rgy S{\"o}l{\'e}tormos and Carsten Stephan and Lori Sokoll and Hoffman, {Barry R.} and Diamandis, {Eleftherios P.} and Sturgeon, {Catharine M} and Duffy, {Michael J} and Ulf-H{\aa}kan Stenman and Hans Lilja and Nils Br{\"u}nner and Chan, {Daniel W} and Richard Babaian and Bast, {Robert C} and Barry Dowell and Esteva, {Francisco J} and Caj Haglund and Nadia Harbeck and Hayes, {Daniel F} and Mads Holten-Andersen and Klee, {George G} and Rolf Lamerz and Looijenga, {Leendert H} and Rafael Molina and Nielsen, {Hans J{\o}rgen} and Harry Rittenhouse and Axel Semjonow and Ie-Ming Shih and Paul Sibley and Gy{\"o}rgy S{\"o}l{\'e}tormos and Carsten Stephan and Lori Sokoll and Hoffman, {Barry R} and Diamandis, {Eleftherios P} and NN NN",

note = "Special report",

year = "2008",

doi = "10.1373/clinchem.2008.105601",

language = "English",

volume = "54",

pages = "e11--79",

journal = "Clinical Chemistry",

issn = "0009-9147",

publisher = "American Association for Clinical Chemistry, Inc.",

number = "12",

}

TY - JOUR

T1 - National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

AU - Sturgeon, Catharine M.

AU - Duffy, Michael J.

AU - Stenman, Ulf-Håkan

AU - Lilja, Hans

AU - Brünner, Nils

AU - Chan, Daniel W.

AU - Babaian, Richard

AU - Bast, Robert C.

AU - Dowell, Barry

AU - Esteva, Francisco J.

AU - Haglund, Caj

AU - Harbeck, Nadia

AU - Hayes, Daniel F.

AU - Holten-Andersen, Mads Nikolaj

AU - Klee, George G

AU - Lamerz, Rolf

AU - Looijenga, Leendert H

AU - Molina, Rafael

AU - Nielsen, Hans Jørgen

AU - Rittenhouse, Harry

AU - Semjonow, Axel

AU - Shih, Ie-Ming

AU - Sibley, Paul

AU - Sölétormos, György

AU - Stephan, Carsten

AU - Sokoll, Lori

AU - Hoffman, Barry R.

AU - Diamandis, Eleftherios P.

AU - Sturgeon, Catharine M

AU - Duffy, Michael J

AU - Stenman, Ulf-Håkan

AU - Lilja, Hans

AU - Brünner, Nils

AU - Chan, Daniel W

AU - Babaian, Richard

AU - Bast, Robert C

AU - Dowell, Barry

AU - Esteva, Francisco J

AU - Haglund, Caj

AU - Harbeck, Nadia

AU - Hayes, Daniel F

AU - Holten-Andersen, Mads

AU - Klee, George G

AU - Lamerz, Rolf

AU - Looijenga, Leendert H

AU - Molina, Rafael

AU - Nielsen, Hans Jørgen

AU - Rittenhouse, Harry

AU - Semjonow, Axel

AU - Shih, Ie-Ming

AU - Sibley, Paul

AU - Sölétormos, György

AU - Stephan, Carsten

AU - Sokoll, Lori

AU - Hoffman, Barry R

AU - Diamandis, Eleftherios P

AU - NN, NN

N1 - Special report

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed. RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node-negative patients. CA15-3/BR27-29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.

AB - BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed. RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node-negative patients. CA15-3/BR27-29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.

U2 - 10.1373/clinchem.2008.105601

DO - 10.1373/clinchem.2008.105601

M3 - Journal article

C2 - 19042984

SN - 0009-9147

VL - 54

SP - e11-79

JO - Clinical Chemistry

JF - Clinical Chemistry

IS - 12

ER -

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this